IS7148A - Methods for producing calcium salt form statins - Google Patents
Methods for producing calcium salt form statinsInfo
- Publication number
- IS7148A IS7148A IS7148A IS7148A IS7148A IS 7148 A IS7148 A IS 7148A IS 7148 A IS7148 A IS 7148A IS 7148 A IS7148 A IS 7148A IS 7148 A IS7148 A IS 7148A
- Authority
- IS
- Iceland
- Prior art keywords
- statins
- methods
- salt form
- calcium salt
- producing calcium
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 159000000007 calcium salts Chemical group 0.000 title 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31281201P | 2001-08-16 | 2001-08-16 | |
| US10/037,412 US6528661B2 (en) | 2000-11-16 | 2001-10-24 | Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| PCT/US2002/026012 WO2003016317A1 (en) | 2001-08-16 | 2002-08-16 | Processes for preparing calcium salt forms of statins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7148A true IS7148A (en) | 2004-02-11 |
Family
ID=26714105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7148A IS7148A (en) | 2001-08-16 | 2004-02-11 | Methods for producing calcium salt form statins |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1425287A4 (en) |
| JP (2) | JP4188826B2 (en) |
| CN (1) | CN100430405C (en) |
| AU (1) | AU2002324715B2 (en) |
| CA (1) | CA2450820C (en) |
| CZ (1) | CZ2004337A3 (en) |
| HR (1) | HRPK20040255B3 (en) |
| HU (1) | HUP0500616A3 (en) |
| IL (2) | IL160077A0 (en) |
| IS (1) | IS7148A (en) |
| MX (1) | MXPA04001451A (en) |
| NO (1) | NO20041082L (en) |
| NZ (1) | NZ529913A (en) |
| PL (1) | PL370407A1 (en) |
| SK (1) | SK1402004A3 (en) |
| TR (1) | TR200302281T2 (en) |
| WO (1) | WO2003016317A1 (en) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| HRP20030454A2 (en) * | 2000-11-16 | 2005-10-31 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-(3,6-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| US7361772B2 (en) | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
| CA2412012C (en) | 2001-11-20 | 2011-08-02 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage |
| EP1485343B1 (en) | 2002-03-18 | 2009-12-23 | Biocon Limited | Amorphous hmg-coa reductase inhibitors of desired particle size |
| EA200401533A1 (en) * | 2002-05-21 | 2005-06-30 | Ранбакси Лабораторис Лимитед | METHOD OF OBTAINING ROSUVASTATIN |
| US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| WO2004072040A1 (en) * | 2003-02-12 | 2004-08-26 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of pitavastatin calcium |
| ES2323366T3 (en) | 2003-04-22 | 2009-07-14 | Biocon Limited | NEW PROCEDURE FOR THE STEREOSELECTIVE REDUCTION OF BETA-CETOSTERS. |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| US7414141B2 (en) | 2003-07-25 | 2008-08-19 | Avecia Pharmaceuticals, Ltd. | Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin |
| WO2005019170A1 (en) * | 2003-08-26 | 2005-03-03 | Biocon Limited | Novel process for preparation of 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl]-3, 5-dihydroxy-6-heptenoic acid sodium salt |
| US7396927B2 (en) | 2003-08-28 | 2008-07-08 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
| EP1816126A1 (en) * | 2003-08-28 | 2007-08-08 | Teva Pharmaceutical Industries Limited | Process for preparation of rosuvastatin calcium |
| UY28501A1 (en) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | CHEMICAL COMPOUNDS |
| WO2005026107A1 (en) | 2003-09-18 | 2005-03-24 | Biocon Limited | Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
| EP1678148A1 (en) * | 2003-10-22 | 2006-07-12 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous rosuvastatin calcium |
| GB0324791D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| WO2005051921A1 (en) | 2003-11-24 | 2005-06-09 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
| CN1894221B (en) * | 2003-12-02 | 2012-08-08 | 特瓦制药工业有限公司 | Reference standard for characterization of rosuvastatin |
| TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
| CA2551549A1 (en) * | 2003-12-29 | 2005-07-14 | Lek Pharmaceuticals D.D. | Process for preparing amorphous (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid |
| CZ200486A3 (en) * | 2004-01-16 | 2005-08-17 | Zentiva, A.S. | Process for the preparation of (E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] (3R, 5S) -3,5-dihydroxy- hemi-calcium salt 6-heptenic acids |
| EP1737828A1 (en) * | 2004-01-19 | 2007-01-03 | Ranbaxy Laboratories Limited | Amorphous magnesium salts of rosuvastatin |
| US7022713B2 (en) * | 2004-02-19 | 2006-04-04 | Kowa Co., Ltd. | Hyperlipemia therapeutic agent |
| SI21745A (en) * | 2004-04-09 | 2005-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Polymorphs of 1-pyrrol-1-heptanoic acid derivative, intermediat for preparation of atorvastatin |
| WO2006017357A1 (en) | 2004-07-13 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step |
| KR20070038553A (en) * | 2004-08-06 | 2007-04-10 | 트렌스폼 파마수티컬스 인코퍼레이티드 | Novel Statin Pharmaceutical Compositions and Related Therapies |
| TWI345562B (en) | 2005-02-22 | 2011-07-21 | Teva Pharma | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof |
| CZ299215B6 (en) * | 2005-06-29 | 2008-05-21 | Zentiva, A. S. | Process for preparing hemi-calcium salt of rosuvastatin, i.e. (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid |
| JP2009515816A (en) * | 2005-08-04 | 2009-04-16 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | Novel formulations comprising fenofibrate and statins and related methods of treatment |
| KR20070062996A (en) | 2005-08-16 | 2007-06-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | Crystalline Rosuvastatin Intermediate |
| CN100371709C (en) * | 2005-12-12 | 2008-02-27 | 重庆医药工业研究院有限责任公司 | A method for separating and measuring pitavastatin and its optical isomers by liquid chromatography |
| SI2024341T1 (en) * | 2006-05-03 | 2016-04-29 | Msn Laboratories Private Limited | Novel process for statins and its pharmaceutically acceptable salts thereof |
| US8404841B2 (en) | 2006-10-09 | 2013-03-26 | Msn Laboratories Limited | Process for the preparation of statins and their pharmaceutically acceptable salts thereof |
| EP2022784A1 (en) | 2007-08-08 | 2009-02-11 | LEK Pharmaceuticals D.D. | Process for the preparation of methyl ester of rosuvastatin |
| US8487105B2 (en) | 2009-01-19 | 2013-07-16 | Msn Laboratories Limited | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof |
| EP2526099B1 (en) | 2010-01-18 | 2016-03-30 | MSN Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
| HUP1000299A2 (en) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation |
| WO2012063254A1 (en) * | 2010-11-12 | 2012-05-18 | Hetero Research Foundation | Novel polymorphs of pitavastatin calcium |
| HU229260B1 (en) * | 2010-11-29 | 2013-10-28 | Egis Gyogyszergyar Nyrt | Process for preparation of rosuvastatin salts |
| CN102875504A (en) * | 2011-07-13 | 2013-01-16 | 华南理工大学 | Application of 4,5,6,7-tetrahydro pravastatin and salts thereof in cardiovascular diseases |
| CN102302452B (en) * | 2011-09-14 | 2012-11-21 | 海南美大制药有限公司 | Pitavastatin calcium lipid solid preparation |
| CN102796036B (en) * | 2012-09-12 | 2014-06-04 | 江苏阿尔法药业有限公司 | Preparation method of atorvastatin calcium |
| CN103724278B (en) * | 2013-12-12 | 2019-03-29 | 江苏阿尔法药业有限公司 | The preparation method of Statins intermediate and its derivative |
| CN106029895B (en) | 2014-02-06 | 2021-07-16 | 株式会社Api | Production method of rosuvastatin calcium and its intermediate |
| KR20160126700A (en) | 2015-04-24 | 2016-11-02 | 미래파인켐 주식회사 | New Statin intermediate, the preparation of the same and the preparation of Rosuvastatin using the same |
| CN105111173B (en) * | 2015-06-26 | 2017-06-23 | 上海应用技术学院 | Statin fluorine-containing derivant and application thereof |
| CN105017231B (en) * | 2015-06-26 | 2018-01-26 | 上海应用技术学院 | Multi-substituted indole statin fluorine-containing modification and use thereof |
| EP3333155B1 (en) | 2015-08-05 | 2023-05-24 | API Corporation | Method for producing pitavastatin calcium |
| CN111362856B (en) * | 2020-04-29 | 2023-08-18 | 福建海西新药创制股份有限公司 | Method for producing atorvastatin calcium by utilizing micro-reaction device |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4137322A (en) * | 1976-11-02 | 1979-01-30 | Sankyo Company Limited | ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents |
| JPS5817443B2 (en) * | 1976-11-02 | 1983-04-07 | 三共株式会社 | Hyperlipidemia therapeutic agent whose main ingredient is ML-236B metal salt |
| US4857547A (en) * | 1988-01-07 | 1989-08-15 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
| BR9609872A (en) * | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi calcium salt of (R- (R * R *)) - 2- (4-fluorophenyl -) - beta delta-dihydroxy-5- (1-methylethyl) -3-phenyl-4- [(phenylamino) carbonyl ] -1H- pyrrole-1heptanoic (atorvastatin) and ristaline |
| US5669156A (en) * | 1996-08-28 | 1997-09-23 | Fleetwood Systems, Inc. | Can end curing system with magnetic fanning and belt conveying |
| NZ503982A (en) * | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
| GB9903472D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
| JP2002538202A (en) * | 1999-03-08 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | Dihydroxy open acid of HMG-CoA reductase inhibitor and salt thereof |
| HRP20030454A2 (en) * | 2000-11-16 | 2005-10-31 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-(3,6-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| AU2007205725A1 (en) * | 2000-11-30 | 2007-08-30 | Teva Pharmaceutical Industries Ltd. | Novel cyrstal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| CA2431068C (en) * | 2000-12-27 | 2008-06-10 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of atorvastatin |
| US7563911B2 (en) * | 2001-08-31 | 2009-07-21 | Morepen Laboratories Ltd. | Process for the preparation of amorphous atorvastin calcium salt (2:1) |
-
2002
- 2002-08-16 CA CA2450820A patent/CA2450820C/en not_active Expired - Fee Related
- 2002-08-16 IL IL16007702A patent/IL160077A0/en active IP Right Grant
- 2002-08-16 EP EP02759374A patent/EP1425287A4/en not_active Withdrawn
- 2002-08-16 JP JP2003521239A patent/JP4188826B2/en not_active Expired - Lifetime
- 2002-08-16 WO PCT/US2002/026012 patent/WO2003016317A1/en not_active Ceased
- 2002-08-16 HR HR20040255A patent/HRPK20040255B3/en not_active IP Right Cessation
- 2002-08-16 HU HU0500616A patent/HUP0500616A3/en unknown
- 2002-08-16 PL PL02370407A patent/PL370407A1/en unknown
- 2002-08-16 SK SK140-2004A patent/SK1402004A3/en not_active Application Discontinuation
- 2002-08-16 CN CNB028159993A patent/CN100430405C/en not_active Expired - Fee Related
- 2002-08-16 MX MXPA04001451A patent/MXPA04001451A/en not_active Application Discontinuation
- 2002-08-16 AU AU2002324715A patent/AU2002324715B2/en not_active Expired - Fee Related
- 2002-08-16 TR TR2003/02281T patent/TR200302281T2/en unknown
- 2002-08-16 CZ CZ2004337A patent/CZ2004337A3/en unknown
- 2002-08-16 NZ NZ529913A patent/NZ529913A/en unknown
-
2004
- 2004-01-27 IL IL160077A patent/IL160077A/en not_active IP Right Cessation
- 2004-02-11 IS IS7148A patent/IS7148A/en unknown
- 2004-03-15 NO NO20041082A patent/NO20041082L/en not_active Application Discontinuation
-
2008
- 2008-07-15 JP JP2008184147A patent/JP2009024008A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRPK20040255B3 (en) | 2006-02-28 |
| WO2003016317A1 (en) | 2003-02-27 |
| JP4188826B2 (en) | 2008-12-03 |
| JP2005500382A (en) | 2005-01-06 |
| JP2009024008A (en) | 2009-02-05 |
| EP1425287A1 (en) | 2004-06-09 |
| IL160077A (en) | 2007-10-31 |
| CZ2004337A3 (en) | 2005-01-12 |
| HUP0500616A2 (en) | 2005-11-28 |
| CA2450820C (en) | 2011-03-15 |
| HRP20040255A2 (en) | 2004-08-31 |
| NZ529913A (en) | 2005-03-24 |
| CA2450820A1 (en) | 2003-02-27 |
| CN100430405C (en) | 2008-11-05 |
| PL370407A1 (en) | 2005-05-30 |
| SK1402004A3 (en) | 2005-01-03 |
| HUP0500616A3 (en) | 2011-07-28 |
| EP1425287A4 (en) | 2005-09-07 |
| CN1543468A (en) | 2004-11-03 |
| NO20041082L (en) | 2004-03-15 |
| AU2002324715B2 (en) | 2009-03-12 |
| IL160077A0 (en) | 2004-06-20 |
| TR200302281T2 (en) | 2004-09-21 |
| MXPA04001451A (en) | 2005-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20041082L (en) | Methods for preparing calcium salt forms of statins | |
| IS7728A (en) | Process for the preparation of rosuvastatin calcium salt | |
| ATE507201T1 (en) | ENERGY-EFFECTIVE CARBONYLATION PROCESS | |
| DE60205413D1 (en) | production method | |
| EP1456132A4 (en) | METHOD OF FRACTIONAL DESIONIZATION | |
| FR2821838B1 (en) | METHOD FOR LIGHTENING PLASTERBOARDS | |
| BR0214746B1 (en) | Method of producing one way clutch | |
| DK1392609T3 (en) | Method for inhibiting the formation of calcium salt deposits | |
| PL367278A1 (en) | Method for inhibiting calcium salt scale | |
| IS7312A (en) | A method for determining the bioactivity of defibrotide | |
| DE60233109D1 (en) | RADIDENTIFICATOR LOCATION PROCESS | |
| IS6716A (en) | Methods for producing cilostasol | |
| ITMI20021031A0 (en) | PROCEDURE FOR PREPARING POLYCARBONATE-POLYOLS | |
| DE60233230D1 (en) | HEIGHT IMAGE SYNTHESIS METHOD | |
| EP1405844A4 (en) | CYCLOALCENONE DERIVATIVE | |
| FI20010892L (en) | Method for producing xylitol | |
| FI20011252A0 (en) | construction method | |
| EP1384958A4 (en) | PRODUCTION SYSTEM | |
| FI20012552L (en) | Method for preparing metal carbonate | |
| ITMO20010199A0 (en) | APPARATUS FOR FORMING TILE | |
| ITMO20010063A0 (en) | APPARATUS FOR FORMING TILE | |
| NO20012603L (en) | Underwater production system | |
| IS6928A (en) | Methods for producing mirtasapine intermediates | |
| ITMI20021432A0 (en) | METHOD FOR PRODUCING CEPHALOSPORINS | |
| FR2832600B1 (en) | HAMAC HORIZONTAL |